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Clinical Implications The increase in food allergy prevalence has coincided
with changes in pertussis vaccine used for infant
immunization. In a prospective birth cohort study, we
report no association between atopic outcomes and type
of vaccine used.TO THE EDITOR:
Pertussis is typically included in most infant vaccination
schedules. The development of atopic sensitization occurs early
in infancy; thus, the infant vaccine schedule may have an impact
on atopic outcomes. A link between pertussis immunization and
risk of atopic disease was ﬁrst suggested for whole-cell pertussis
(wP),1,2 although the published data strongly suggest that these
concerns are unwarranted.3-5
More recently, many countries have switched from wP to
acellular pertussis (aP), a measure instituted to reduce the rela-
tively higher rate of adverse events associated with wP immuni-
zation. The aP vaccine drives a TH2-like immune response in
contrast to the wP vaccine,6,7 which might predispose to atopic
disease. Public health bodies in the United States, Australia, and
Europe have noted that in some countries, the increase in
prevalence of food allergy in the last few decades has coincided
with the switch from wP to aP. There are no published studies
assessing how the risk of atopic disease is affected by type of
pertussis immunization, although data suggest that IgE produc-
tion following a booster with aP appears to be speciﬁc for
pertussis-related antigens and not for food or environmental
allergens.8
In the United Kingdom, the switch from wP to aP occurred in
2004. However, in 1999-2001, a shortage in the supply of wP
resulted in the release of aP to meet demand. This period
coincided with the establishment of a birth cohort study to assess
the epidemiology of atopic disease. As a result, infants included
in the birth cohort received a mix of wP and aP almost at
random, depending on the supply of the particular vaccine,
avoiding potential biases due to secular trends in the risk of
developing atopic disease.
The Food Allergy and Intolerance Research (FAIR) birth
cohort included all 1063 babies born on the Isle of Wight (UK)
between September 2001 and August 2002. A total of 969
(91%) parents consented to allergy assessments being performed
on their child at age 1, 2, 3, and 10 years.9 Symptoms of allergic
disease were assessed using validated questionnaires,4 incombination with parent interview. Information on family his-
tory and history of allergic disease was obtained by questionnaire.
Children underwent skin prick tests (SPTs) to a standard panel
of predeﬁned food (milk, egg, wheat, peanut, sesame, and cod
ﬁsh) and aeroallergens (house dust mite Dermatophagoides pter-
onyssinus, cat, and grass). A positive SPT result was deﬁned as a
mean wheal size of 3 mm or more. Children with a history of
possible allergic reaction and/or positive SPT result to a food
were invited to undergo oral food challenge (double-blind
placebo-controlled food challenge).9
We obtained data relating to vaccine status (type of vaccine,
date given) of children included in the FAIR cohort from a
centralized register held by Public Health England. A selection
of paper child-health records was cross-referenced with this data
set to conﬁrm data integrity. Analysis was limited to children
who received their ﬁrst dose of pertussis vaccine between the
age of 6 weeks and 18 weeks and in whom the type of vaccine
was recorded. To compare the risks of allergy according to aP
and wP exposure, we performed multivariable binomial
regression to derive crude relative risks and relative risks
adjusted for potential confounders of family history of asthma/
hay fever, breast-feeding, and sex. Ethical approval for the study
was obtained from the South Central e Southampton B
Research Ethics Committee (REF 10/H0504/11), with data
linkage under separate approval granted to Public Health
England.
Details regarding the ﬁrst pertussis vaccine administered
were available for 906 children: 71 received their dose after age
18 weeks, and were therefore excluded, while in 16 children,
we were unable to determine the type of pertussis vaccine
administered. Thus, 819 children were included in the initial
analysis, of whom 224 (27%) received their ﬁrst vaccine dose
containing aP (and the remaining 595 [73%] wP). No sig-
niﬁcant associations were identiﬁed between any outcome
measure and type of pertussis vaccine used for the ﬁrst infant
vaccine (Table I).
To assess whether receipt of any dose of aP was associated
with a change in risk, we performed a further analysis in 701
children who received 3 doses of pertussis according to the
immunization schedule and in whom data regarding the type
of vaccine (aP vs wP) were available. A total of 343 (48.9%)
received at least 1 dose of aP, whereas 351 (50.1%) received
wP for all 3 doses. No signiﬁcant associations were identiﬁed
between any outcome measure and administration of at least 1
dose of aP in the ﬁrst year of life (Table II). We also assessed
for any effect on outcome by dosing trend; that is, which
vaccine (aP or wP) was used for each dose: no signiﬁcant as-
sociations were identiﬁed (Table II).
In summary, we did not identify any evidence for an associ-
ation between type of pertussis vaccine given and allergic/atopic
outcomes in this cohort. The strengths of this study include the
almost random allocation of vaccine (wP vs aP), prospective data
collection, use of objective assessments, and high rate of follow-
up; however, our analysis is limited by the size of this cohort and
we cannot, therefore, exclude a more subtle effect of acellular
pertussis on subsequent atopy.1
TABLE II. RRs of atopic outcomes in those receiving any dose of aP vs none (ie, wP used for all 3 immunizations), adjusted for potential
confounders
Outcome Any aP, n/N* (%)
No aP (ie, wP used
for all 3 doses),
n/N* (%)
RR (95% CI)
(any aP vs none)
Fisher exact
P value
Adjusted RR†
(any aP vs none) P value
Trend per dose
(adjusted RR†
per aP dose)
IgE-mediated food allergy, ever 10/340 (2.9%) 8/356 (2.2%) 1.30 (0.52-3.28) .64 1.16 (0.46-2.97) .75 1.17 (0.75-1.80)
Positive SPT result to food, ever 13/274 (4.7%) 16/297 (5.4%) 0.88 (0.43-1.79) .85 0.76 (0.37-1.58) .47 0.87 (0.59-1.27)
Asthma, by age 3 y 37/315 (11.7%) 32/341 (9.4%) 1.25 (0.80-1.96) .35 1.13 (0.71-1.80) .62 1.12 (0.90-1.38)
Asthma, by age 10 y 41/178 (23.0%) 37/220 (16.8%) 1.37 (0.92-2.04) .13 1.21 (0.79-1.87) .39 1.04 (0.84-1.29)
Eczema, at 6 mo 125/328 (38.1%) 145/346 (41.9%) 0.91 (0.76-1.09) .35 0.88 (0.73-1.05) .17 0.94 (0.86-1.04)
Eczema, at 1 y 56/325 (17.2%) 73/345 (21.1%) 0.81 (0.60-1.11) .20 0.82 (0.59-1.12) .21 0.91 (0.78-1.08)
Eczema at 3 y 56/313 (17.9%) 70/338 (20.7%) 0.86 (0.63-1.18) .37 0.85 (0.62-1.17) .32 0.95 (0.81-1.12)
Allergic rhinitis, by age 10 y 80/301 (26.6%) 98/322 (30.4%) 0.87 (0.68-1.12) .33 0.88 (0.68-1.13) .31 0.95 (0.84-1.08)
Any positive SPT result
to aeroallergen, ever
73/311 (23.5%) 60/332 (18.1%) 1.30 (0.96-1.76) .10 1.17 (0.86-1.60) .31 1.11 (0.96-1.28)
Sensitized to HDM, ever 43/187 (23.0%) 36/217 (16.6%) 1.39 (0.92-2.06) .13 1.14 (0.75-1.73) .54 1.13 (0.94-1.36)
Any atopy 77/312 (24.7%) 64/332 (19.3%) 1.28 (0.95-1.72) .11 1.16 (0.86-1.57) .32 1.09 (0.95-1.26)
HDM, House dust mite; RR, relative risk.
We also assessed for any effect on outcome by dosing trend, ie, which vaccine (aP or wP) was used for each dose. The 95% CIs for the RRs show the precision of estimates for
the different outcomes.
*Where denominators do not add up to 701, this is due to missing data.
†Adjusted for family history of asthma/hay fever, breast-feeding, and sex.
TABLE I. RRs of atopic outcomes in those receiving a first dose of aP vs wP, adjusted for potential confounders
Outcome First dose aP, n/N* (%) First dose wC, n/N* (%) RR (95% CI)
Fisher exact
P value Adjusted RR† P value
IgE-mediated food allergy, ever 5/223 (2.2%) 19/591 (3.2%) 0.70 (0.26-1.84) .64 0.78 (0.29-2.07) .62
Positive SPT result to food, ever 5/174 (2.9%) 30/465 (6.5%) 0.45 (0.18-1.13) .08 0.46 (0.18-1.17) .10
Asthma, by age 3 y 22/204 (10.8%) 54/560 (9.6%) 1.12 (0.70-1.79) .68 1.16 (0.71-1.87) .55
Asthma, by age 10 y 28/112 (25.0%) 60/336 (17.9%) 1.40 (0.94-2.08) .10 1.15 (0.73-1.81) .55
Eczema, at 6 mo 84/217 (38.7%) 230/568 (40.4%) 0.96 (0.79-1.16) .68 0.84 (0.77-1.15) .54
Eczema, at 1 y 35/212 (16.5%) 112/564 (19.95) 0.83 (0.59-1.17) .31 0.84 (0.59-1.20) .35
Eczema at 3 y 40/202 (19.8%) 103/556 (18.5%) 1.07 (0.77-1.48) .68 1.06 (0.76-1.47) .74
Allergic rhinitis, by age 10 y 54/191 (28.2%) 142/526 (27.0%) 1.05 (0.80-1.37) .78 1.05 (0.81-1.38) .70
Any positive SPT result to
aeroallergen, ever
49/202 (24.3%) 99/538 (18.4%) 1.32 (0.97-1.78) .08 1.24 (0.90-1.69) .19
Sensitized to HDM, ever 30/118 (25.4%) 56/320 (17.5%) 1.45 (0.98-2.14) .08 1.30 (0.86-1.98) .22
Any atopy 51/203 (25.1%) 106/538 (19.7%) 1.27 (0.95-1.71) .11 1.19 (0.88-1.62) .25
HDM, House dust mite; RR, relative risk.
The 95% CIs for the RRs show the precision of estimates for the different outcomes.
*Where denominators do not add up to 819, this is due to missing data.
†Adjusted for family history of asthma/hay fever, breast-feeding, and sex.
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